Isotretinoin achieved acne clearance in nearly two-thirds of transgender individuals on masculinizing hormone therapy, according to a recent study.
The study, a multicenter retrospective case series published in JAMA Dermatology, included 55 patients from 4 medical centers and focused on treatment outcomes, adverse effects, and reasons for discontinuation.
Participants aged 12-49 years (mean age, 25.4) showed significant improvement, with 87.3% experiencing better acne control and 47.3% achieving complete clearance. Among those treated with a cumulative dose of 120 mg/kg or more, 97% improved, and 63.6% cleared.
Researchers reported that common side effects were dryness (80%), joint pain (14.5%), headaches (10.9%), and eczema (9.1%). They also noted that premature discontinuation due to adverse effects, cost, pharmacy issues, and logistical problems was linked to poorer outcomes.
"The results of this case series study suggest that isotretinoin may play an underappreciated role in gender-affirming care," stated researchers. To improve patient outcomes, they called for further efforts to understand optimal dosing and treatment barriers.
The authors reported no conflicts of interest. The study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases.